Target Pool. OncoGenex will have a pool (the “Target Pool”) containing up to 2 slots for which OncoGenex can designate certain gene targets for collaborative research, development and commercialization under this Agreement (each such slot, a “Target Slot” and any gene target occupying such a slot, a “Collaboration Gene Target”). OncoGenex must designate at least one Collaboration Gene Target within the first 6 months following the Effective Date and the second Collaboration Gene Target within the first 24 months following the Effective Date. If OncoGenex fails to designate a Collaboration Gene Target by the applicable deadline above, it will lose its right to designate such Collaboration Gene Target.
Target Pool. As of the Effective Date, Regulus and AstraZeneca have identified in the R&D Plan three microRNAs as potential Oncology Targets (the “Target Pool” and each such microRNA properly included in the Target Pool, a “Target Pool microRNA”). Regulus represents that as of the Effective Date they are not aware of any Target Encumbrances other than the Regulus Existing Agreements for the Target Pool as of the Effective Date. During the first 12 months of the Research Term (or such longer time period during the Research Term as may be set forth in the R&D Plan), the JSC may substitute a different microRNA for an existing Target Pool microRNA; provided, that such substitute microRNA (i) is not the subject of an exclusive license or option for an exclusive license granted by Regulus to a Third Party or any other obligations of Regulus or its Affiliates that would prohibit Regulus from collaborating with AstraZeneca under this Agreement or from granting a license under Section 2.1 with respect to such microRNA, (ii) is not a Regulus Independent Program, and (iii) is primarily associated with the Oncology Field and
Target Pool. The Target Pool, as defined herein (“Target Pool”), identifies up to [***] gene targets including the gene targets selected for collaborative Research, Development and Commercialization under the Research Program (each such gene target is a “Selected Gene Target”). The number of Selected Gene Targets is initially limited to [***], but this limit may be increased as contemplated by clause (iii) of Section 3.6.2 below or upon mutual written agreement of the Parties. The gene targets that are part of the Target Pool (including which of such gene targets are the Selected Gene Targets and whether such gene target is in “Stage 1” or “Stage 2” under the R&D Plan) will be listed on APPENDIX 12, which may be updated from time to time by the Parties in accordance with this Agreement. OMI will have [***] following the Effective Date to designate the initial gene targets it wants to place in the Target Pool. In addition, OMI, at a minimum, must select the first [***] Selected Gene Targets on or before the Effective Date.
Target Pool. As of the Effective Date, Regulus and AstraZeneca have identified in the R&D Plan three microRNAs as potential Oncology Targets (the “Target Pool” and each such microRNA properly included in the Target Pool, a “Target Pool microRNA”). Regulus represents that as of the Effective Date they are not aware of any Target Encumbrances other than the Regulus Existing Agreements for the Target Pool as of the Effective Date. During the first 12 months of the Research Term (or such longer time period during the Research Term as may be set forth in the R&D Plan), the JSC may substitute a different microRNA for an existing Target Pool microRNA; provided, that such substitute microRNA (i) is not the subject of an exclusive license or option for an exclusive license granted by Regulus to a Third Party or any other obligations of Regulus or its Affiliates that would prohibit Regulus from collaborating with AstraZeneca under this Agreement or from granting a license under Section 2.1 with respect to such microRNA, (ii) is not a Regulus Independent Program, and (iii) is primarily associated with the Oncology Field and (iv) Regulus will provide information on any Target Encumbrances applicable to such substitute microRNA, subject to Regulus’ confidentiality obligations in its Third Party Agreements. If the JSC substitutes a new microRNA for a prior Target Pool microRNA, then such new microRNA shall be a Target Pool microRNA, and such prior Target Pool microRNA shall not be a Target Pool microRNA. For clarity, in no event shall there be more than three microRNAs in the Target Pool at any time. For the avoidance of doubt any substitutions described in Section 3.4.2(a) are independent of the rights of substitution and substitution target as described in Section 3.4.3. As of the Effective Date, the Parties agree that the Target Pool consists of the […***…], as described in the R&D Plan as of the Effective Date.
Target Pool
